Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients.
|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical Cancer Research|
|State||Published - Nov 15 2021|
ASJC Scopus subject areas
- Cancer Research